Monday, March 09, 2009

Applied Biosystems and Translational Genomics Research Institute Accelerate use of Genomics Research for Medical Applications

Enhanced understanding of genetic basis of disease to hasten advent of personalized medicine

Phoenix, AZ – March 9, 2009 – Applied Biosystems, a division of Life Technologies Corporation (NASDAQ: LIFE), and the Translational Genomics Research Institute, today announced a strategic alliance designed to accelerate research into complex diseases and medical conditions. As part of this alliance, a team of scientists from TGen and Applied Biosystems will employ the SOLiD™ 3 System, Applied Biosystems’ next-generation genomic analysis platform, to sequence DNA from thousands of patients with a variety of diseases. The goal of this research is to translate scientific discoveries at the genetic level into knowledge about the underlying causes of disease that may ultimately be used to create cutting-edge tools for use in clinical diagnosis.

The alliance enables TGen researchers to apply best-of-breed sequencing technology across a broad spectrum of research efforts that focus on developing a more personalized approach to medicine. This approach, which is known as personalized medicine, represents a potential clinical shift from treatment of disease based on symptoms, to therapy that is specific to an individual’s unique genetic make up. Among the goals of this project is to advance the promise of personalized medicine by reducing the cost of genome sequencing to make it a routine diagnostic tool in medical care.

“This strategic alliance will accelerate genomic discoveries by integrating relevant scientific findings into the clinical setting,” said Mark Stevenson, President and Chief Operating Officer of Life Technologies. “The SOLiD System will help this team of scientists and other researchers and clinicians interpret how genetic variation can improve the ability to create more effective therapeutic solutions, bringing personalized medicine one step closer to mainstream application.”

The scientists involved in this alliance will utilize a total of five SOLiD 3 Systems to build a sequencing pipeline in connection with patient-centric, medically-directed resequencing on a cross section of patient samples. The results are expected to positively impact individuals with cancer, autoimmune and neurological disorders. The alliance will also involve the co-development of a bioinformatics analysis and visualization pipeline for the SOLiD platform. This will result in software tools designed to ease the analytical challenges associated with analyzing the vast amounts of data generated by human disease and cancer genomics applications of next generation sequencing.

Dr. Jeffrey Trent, President and Scientific Director of TGen, and other renowned principal investigators will partner with Applied Biosystems scientists to perform six different projects focused on comprehensive characterization of genetic and molecular changes occurring within clinical cohorts for each disease. The scientists at TGen chose the SOLiD technology for this project, due to its inherent scalability, unparalleled throughput and unmatched data accuracy. These attributes make the SOLiD System uniquely suited for translational research of complex diseases by enabling the detection of single nucleotide polymorphisms and other structural variation across the genome in large numbers of samples.

“Consistent with TGen’s mission of developing the next generation of diagnostics and therapeutics, the alliance with Applied Biosystems forges ties with a key industry partner whose technologies align seamlessly with our research objectives and should produce accelerated progress in our efforts to better understand the genetic underpinnings of many diseases, with a particular emphasis on cancer,” said Dr. Trent.

Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. The technologies it markets include a robust line of DNA sequencing systems and chemistries to meet the increasing demands of the scientific community for higher throughput, more sophisticated DNA sequencing solutions. Applied Biosystems, together, with Invitrogen – a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics – is part of Life Technologies Corporation, which markets the life science industry’s most comprehensive portfolio of solutions for molecular and cell biology. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world.

TGen is a growing leader in integrating medically directed technologies and applications into clinical practice, the results of which provide real solutions for patients. Through its recent alliance with the Van Andel Research Institute in Grand Rapids, Michigan, TGen and VARI now have a national outreach to patient populations across multiple diseases. That alliance combines the groundbreaking basic research expertise of VARI with the cutting-edge translational genomics and analysis capabilities of TGen.

For more information, please visit: www.appliedbiosystems.com, www.invitrogen.com and www.tgen.org

About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org

Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

Labels: , , , , , ,

Tuesday, February 17, 2009

High Tea Raises High Hopes For Tgen Ovarian Cancer Research

High tea raises high hopes for TGen ovarian cancer research

PHOENIX, Ariz. - Feb. 16, 2009 - The Anne Rita Monahan Foundation will host Tea for Teal, a high English afternoon tea, to fund ovarian cancer research by the Translational Genomics Research Institute (TGen).

The Tea for Teal is at 2 p.m. Saturday, Feb. 28, at the Sheraton Downtown Phoenix, 340 N. Third St., part of the Anne Rita Monahan Foundation's efforts to raise $100,000 for ovarian cancer research.

Just as pink is the color representing the fight against breast cancer, teal is the color that represents the fight against ovarian cancer.

Funds will be used to research early-stage, drug-resistant ovarian cancer. TGen scientists are searching for a reliable early-screening tool and better drug treatments.

The Anne Rita Monahan Foundation was established by Anne Rita Monahan of Phoenix, a heroic ovarian cancer fighter, in an effort to warn other women about the disease, which she continues to fight daily.

Because the disease is often difficult to detect in its early stages, the Anne Rita Monahan Foundation is focused on education about the early signs and symptoms of ovarian cancer. The Foundation also funds research into the discovery of an effective, reliable screening tool that would help detect this type of cancer as soon as possible, giving women the best opportunities for remission.

The Anne Rita Monahan (ARM) Foundation's effort to eradicate ovarian cancer includes outreach and educational programs for the public and for the medical community. The Foundation urges women to "ARM Yourself Against Ovarian Cancer."

Anne Rita Monahan Foundation Tea for Teal

For more information or to register:

www.anneritamonahan.org or 602-264-5539.

Participation fees:

Individual tickets are $60; a table of 10 is $500.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to the performance of groundbreaking research with life changing results. Research at TGen is focused on developing earlier diagnostics and smarter treatments for diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated to the diagnosis and treatment of disease in a manner tailored to individual patients.


Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

Labels: , , , , , , , , , ,